Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells

Cancer Research

Volumn 68, Issue 1, 2008, Pages 236-248

  Tan, Shyh Han ^a   Dagvadorj, Ayush ^a   Shen, Feng ^a   Gu, Lei ^a   Liao, Zhiyong ^a   Abdulghani, Junaid ^a   Zhang, Ying ^b   Gelmann, Edward P ^b   Zellweger, Tobias ^c   Culig, Zoran ^e   Visakorpi, Tapio ^f   Bubendorf, Lukas ^d   Kirken, Robert A ^g   Karras, James ^h   Nevalainen, Marja T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c St Clara Hospital   (Netherlands)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY OF TAMPERE   (Finland)

^g UNIVERSITY OF TEXAS AT EL PASO   (United States)

^h ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ESTROGEN; STAT5A PROTEIN; STAT5B PROTEIN; ANDROGEN; STAT5 PROTEIN;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ACTIVE TRANSPORT; CELL CULTURE; CELL NUCLEUS; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOPRECIPITATION; MALE; METABOLISM; NEOPLASM; PROSTATE TUMOR; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANDROGENS; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN INTERACTION MAPPING; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 39149111601     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2972     Document Type: Article

References (50)

1. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004;10:26-7.
2. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
3. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
4. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-9.
5. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
6. Buchanan G, Yang M, Harris JM, et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 2001;15:46-56.
7. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-7.
8. Rui H, Djeu JY, Evans GA, Kelly PA, Farrar WL. Prolactin receptor triggering. Evidence for rapid tyrosine kinase activation. J Biol Chem 1992;267:24076-81.
9. Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology 1994;135:1299-306.
10. Nevalainen MT, Ahonen TJ, Yamashita H, et al. Epithelial defect in prostates of Stat5a-null mice. Lab Invest 2000;80:993-1006.
11. Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 2002;143:228-38.
12. Li H, Ahonen TJ, Alanen K, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004;64:4774-82.
13. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997;99:618-27.
14. Nevalainen MT, Valve EM, Makela SI, Blauer M, Tuohimaa PJ, Harkonen PL. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 1991;129:612-22.
15. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 1999;140:5412-21.
16. Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410-5.
17. Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 2002;53:24-33.
18. Kindblom J, Dillner K, Sahlin L, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003;144:2269-78.
19. Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. Endocrinology 1998;139:3691-5.
20. Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL. Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 1996;137:3078-88.
21. Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Harkonen PL. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 1997;11:1297-307.
22. Ahonen TJ, Xie J, LeBaron MJ, et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003;278:27287-92.
23. Kazansky AV, Spencer DM, Greenberg NM. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 2003;63:8757-62.
24. Li H, Zhang Y, Glass A, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 2005;11:5863-8.
25. Zhang Y, Glass A, Bennett N, Oyama KA, Gehan E, Gelmann EP. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer 2004;100:300-7.
26. Saramaki O, Willi N, Bratt O, et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 2001;159:2089-94.
27. Nevalainen MT, Xie J, Torhorst J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004;22:2053-60.
28. Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002;16:1108-24.
29. Behbod F, Nagy ZS, Stepkowski SM, et al. Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells. J Immunol 2003;171:3919-27.
30. Trachtenberg J, Walsh PC. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 1982;127:466-71.
31. Ganguly TC, O'Brien ML, Karpen SJ, Hyde JF, Suchy FJ, Vore M. Regulation of the rat liver sodium-dependent bile acid cotransporter gene by prolactin. Mediation of transcriptional activation by Stat5. J Clin Invest 1997;99:2906-14.
32. Matsumura I, Kitamura T, Wakao H, et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999;18:1367-77.
33. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBOJ 1994;13:4361-9.
34. Ku CY, Loose-Mitchell DS, Sanborn BM. Both Sertoli and peritubular cells respond to androgens with increased expression of an androgen response element reporter. Biol Reprod 1994;51:319-26.
35. Kasper S, Rennie PS, Bruchovsky N, et al. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 1994;269:31763-9.
36. Gregory CW, He B, Wilson EM. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 2001;27:309-19.
37. Black BE, Paschal BM. Intranuclear organization and function of the androgen receptor. Trends Endocrinol Metab 2004;15:411-7.
38. Chekmenev DS, Haid C, Kel AE. P-Match: transcription factor binding site search by combining patterns and weight matrices. Nucleic Acids Res 2005;33:W432-7.
39. Lin D-L, Keller ET. Mechanism of interleukin-6 promotion of androgen receptor function in prostate cancer cells. Iowa City: International Conference on Prostate Cancer Research; 1999.
40. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999;19:5143-54.
41. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-63.
42. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277:7076-85.
43. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60:2132-5.
44. Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J 1997;16:7067-77.
45. McBride KM, Banninger G, McDonald C, Reich NC. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-α. EMBO J 2002;21:1754-63.
46. Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR. How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBOJ 2000;19:4111-22.
47. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-64.
48. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
49. Clark J, Edwards S, Feber A, et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 2003;22:1247-52.
50. Gillanders EM, Xu J, Chang BL, et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004;96:1240-7.